trial

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

NCTId NCT05443724
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 700 (actual)
Sponsored by AbbVie
Primary completion 2025-06-25
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
700 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2022-09-02
Primary completion
2025-06-25
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Emraclidine

Sponsors

AbbVieLead Sponsor

Sites

85 total
Phoenix, United StatesBryant, United StatesLittle Rock, United StatesAnaheim, United StatesBellflower, United StatesCulver City, United StatesGarden Grove, United StatesLa Habra, United StatesLemon Grove, United StatesMontclair, United StatesOrange, United StatesPico Rivera, United States

Linked catalysts

1
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Pa — primary completion2025-06-25

Facts & assertions

4 sourced
Enrollment
700
Phase
PHASE2
Primary Completion Date
2025-06-25
Status
COMPLETED
relationships
The graph out of here
drug
Emraclidine
drug
lead_sponsor
AbbVie
company
indication
Schizophrenia
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia
indication